Zacks upgrades EndoChoice to “buy”: 4 notes

Zacks Investment Research upgraded EndoChoice from a “hold” rating to a “buy” rating, according to a report by The HillTop News.

Advertisement

Here are four notes:

1. EndoChoice currently has a consensus rating of “buy” and an average target price of $16.31.

2. The company has a one-year low of $3.70 and a one-year high of $19.69.

3. The firm has a 50-day moving average of $5.03 and a 200-day moving average of $9.44.

4. EndoChoice’s market capitalization is $117.28 million.

More articles on GI/endoscopy:
GI physician leader to know: Dr. Neena Abraham of Mayo Clinic
5 most read GI/endoscopy stories: Week of Feb. 29 – March 4
St. Francis Regional, Ridgeview medical centers come together for GI care: 4 things to know

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.